New type of immunotherapy may offer longer survival in melanoma
Source: The Pharmale Letter, May 2022
Enrollment in a Dutch trial of tilsotolimod, Idera Pharmaceuticals’ (Nasdaq: IDRA) synthetic Toll-like receptor 9 agonist, has been stopped early.
The Pennsylvania, USA-based company said positive interim results from the Phase II INTRIM 1 study were enough to draw a line under enrollment for the primary endpoint.
The news sent the firm’s shares up 16% to $0.41 by close of trading on Tuesday.
READ THE ORIGINAL FULL ARTICLE